CytRx PhIIb cancer survival data fail to impress

CytRx released some unimpressive overall survival rates from its Phase IIb study of its aldoxorubicin compared with doxorubicin for soft tissue sarcoma. Overall median OS in the drug arm was 16 months, compared with an uncomfortably close 14 months in the comparison arm of the study. The biotech, though, noted that the study had not been powered to produce statistically significant results. CytRx ($CYTR) shares slipped slightly on the news this morning. Just yesterday the FDA lifted a partial hold on the late-stage program. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.